MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers16213558

Медицинская библиотека · Cancers · 2024

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.

Weichenthal Michael, Mangana Joanna, Gavrilova Iva, Lugowska Iwona, Shalamanova Gergana Krumova, Kandolf Lidija, Chiarion-Sileni Vanna, Mohr Peter, Karanikolova Teodora Sotirova, Teterycz Pawel, Espinosa Enrique, Schnecko Philipp, Cheng Phil, Bender Marc, Jiang Shan, Burke Thomas, Ascierto Paolo Antonio, Gogas Helen, Rodas Ivan Marquez, Rutkowski Piotr, Schadendorf Dirk, Dummer Reinhard, For The EUMelaReg Consortium

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma.

METHODS

We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy for stage III and unresectable stage IV melanoma and overall survival (OS) from initiation of pembrolizumab.

RESULTS

Patients were stratified according to age, sex, BRAF status, number of positive lymph nodes and disease substage. Median TOT was 11.1 (9.2-11.5) months, median RFS was 29.6 [18.7-not reached (NR)] months and median DMFS was 32.4 (22.7-NR) months. TTNT was 29.9 (22.2-NR) months, while median OS was not reached.

CONCLUSIONS

The results of this study offer insights into the real-world use of pembrolizumab as an adjuvant therapy for melanoma in Europe.

Для цитирования: Weichenthal Michael, Mangana Joanna, Gavrilova Iva, Lugowska Iwona, Shalamanova Gergana Krumova, Kandolf Lidija, Chiarion-Sileni Vanna, Mohr Peter, Karanikolova Teodora Sotirova, Teterycz Pawel, Espinosa Enrique, Schnecko Philipp, Cheng Phil, Bender Marc, Jiang Shan, Burke Thomas, Ascierto Paolo Antonio, Gogas Helen, Rodas Ivan Marquez, Rutkowski Piotr, Schadendorf Dirk, Dummer Reinhard, For The EUMelaReg Consortium. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.. Cancers. 2024. DOI: 10.3390/cancers16213558.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.